FDA Approves Moderna's mRNA-Based Flu Vaccine Amid Funding Cuts
The FDA has approved Moderna's mRNA-based flu vaccine for adults aged 50 and older, marking a significant milestone as it is the first time mRNA technology, previously used in COVID-19 vaccines, has been approved for seasonal flu prevention. This approval comes at a time when federal funding for mRNA vaccine research has been significantly reduced, raising concerns about the future of mRNA technology development. Smaller companies and universities, which rely heavily on government funding for clinical trials, may face challenges in advancing new vaccines due to these cuts. Despite the funding issues, Moderna has managed to fund its research independently, allowing the flu vaccine to be available within weeks. 
